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Abstract
Background: Cholinesterase inhibitors are commonly used to treat dementia. These drugs enhance the effects of
acetylcholine, and reports suggest they may precipitate bradycardia in some patients. We aimed to examine the association
between use of cholinesterase inhibitors and hospitalization for bradycardia.
Methods and Findings: We examined the health care records of more than 1.4 million older adults using a case-time-
control design, allowing each individual to serve as his or her own control. Case patients were residents of Ontario, Canada,
aged 67 y or older hospitalized for bradycardia between January 1, 2003 and March 31, 2008. Control patients (3:1) were not
hospitalized for bradycardia, and were matched to the corresponding case on age, sex, and a disease risk index. All patients
had received cholinesterase inhibitor therapy in the 9 mo preceding the index hospitalization. We identified 1,009
community-dwelling older persons hospitalized for bradycardia within 9 mo of using a cholinesterase inhibitor. Of these,
161 cases informed the matched analysis of discordant pairs. Of these, 17 (11%) required a pacemaker during
hospitalization, and six (4%) died prior to discharge. After adjusting for temporal changes in drug utilization, hospitalization
for bradycardia was associated with recent initiation of a cholinesterase inhibitor (adjusted odds ratio [OR] 2.13, 95%
confidence interval [CI] 1.29–3.51). The risk was similar among individuals with pre-existing cardiac disease (adjusted OR
2.25, 95% CI 1.18–4.28) and those receiving negative chronotropic drugs (adjusted OR 2.34, 95% CI 1.16–4.71). We found no
such association when we replicated the analysis using proton pump inhibitors as a neutral exposure. Despite
hospitalization for bradycardia, more than half of the patients (78 of 138 cases [57%]) who survived to discharge
subsequently resumed cholinesterase inhibitor therapy.
Conclusions: Among older patients, initiation of cholinesterase inhibitor therapy was associated with a more than doubling
of the risk of hospitalization for bradycardia. Resumption of therapy following discharge was common, suggesting that the
cardiovascular toxicity of cholinesterase inhibitors is underappreciated by clinicians.
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Cholinesterase inhibitors such as donepezil, rivastigmine, and
galantamine are widely prescribed to improve cognitive function
in patients with Alzheimer disease—a condition expected to
quadruple in prevalence over the next 50 y [1]. By inhibiting the
synaptic metabolism of acetylcholine, these drugs enhance cortical
cholinergic neurotransmission [2]. Although cholinesterase inhib-
itors are generally well tolerated, they may provoke adverse effects
in some patients because their cholinergic effects are not confined
to the central nervous system [2]. Symptoms of cholinergic excess
are often nonspecific and include gastrointestinal upset, diarrhea,
hypersalivation, and muscle cramps. In severe instances, these
drugs can increase vagal tone and thereby precipitate bradycardia.
Anecdotal reports, small observational studies, and post hoc
analyses of clinical trials have produced conflicting results, with
some suggesting an increased risk of bradycardia during
cholinesterase inhibitor therapy and others finding no such
association [3–12]. At the time of our study, no large-scale studies
had examined, to our knowledge, whether cholinesterase inhibitor
use among older patients predisposes to bradycardia.
Frail older adults represent a growing population of cholines-
terase inhibitor users. These patients are more prone to the
adverse effects of drugs and discontinue cholinesterase inhibitors
more often than patients in clinical trials, who are typically
healthier than those in clinical practice [10]. We sought to
characterize the association between cholinesterase inhibitor
therapy and hospitalization for bradycardia in a population of
more than 1.4 million older adults.
Methods
Setting and Data Sources
We linked multiple population-based health care databases in
an anonymous fashion using unique encrypted health card
numbers. This linkage process has been standardized by our
research institution (http://www.ices.on.ca), and these methods
have been used extensively to study population-based health
outcomes, including adverse drug events [13–20]. The Ontario
Drug Benefit database was used to identify prescription records,
and contains comprehensive, high-quality information regarding
prescription medications dispensed to Ontario residents aged 65 y
and older [21]. The Canadian Institute for Health Information
(CIHI) Discharge Abstract Database was used to identify hospital
admissions, and contains detailed diagnostic and procedural
information for all hospital admissions in Ontario. The National
Ambulatory Care Reporting System was used to identify visits to
emergency departments. Basic demographic information was
obtained from the Ontario Registered Persons Database. Finally,
we used the Ontario Health Insurance Plan database to identify
claims for inpatient and outpatient physician services. All Ontario
seniors receive universal access to hospital care, physicians’
services, and prescription drug coverage. The study was approved
by the Research Ethics Board of Sunnybrook Health Sciences
Centre.
Study Design
We used the case-time-control design to examine the association
between cholinesterase inhibitor use and hospitalization for
bradycardia among Ontario residents aged 67 y and older. This
design is an extension of the case-crossover design first described
by Maclure [22,23], which compares within-patient exposure to a
potential risk factor in the period immediately preceding a putative
adverse event (the risk interval) to exposure during a different time
(the reference interval). Because cases serve as their own controls,
fixed patient characteristics are controlled for implicitly under this
design [24,25]. However, the case-crossover design can be
vulnerable to spurious associations between a drug and an
outcome owing to temporal trends in drug utilization. The case-
time-control design corrects for this limitation by incorporating a
control group of patients who did not experience the outcome of
interest [22,26–28].
Identification of Case Patients
We included all patients aged 67 y and older hospitalized with a
diagnosis of bradycardia between January 1, 2003 and March 31,
2008, and restricted our analysis to those patients who were
exposed to a cholinesterase inhibitor in the 9 mo prior to the index
date. Because we hypothesized that bradycardia caused by
cholinesterase inhibitors would be most likely to manifest during
the initial period of therapy, we defined our risk interval as the 3-
mo period immediately preceding hospitalization, and our
reference interval as the months seven through nine prior to the
index date (Figure 1). We included a 3-mo wash-out interval
between the risk and reference intervals to avoid contamination
between the risk and reference intervals, and excluded individuals
with pacemaker insertion in the previous 5 y or hospitalization in
the year preceding the study entry. Individuals with cholinesterase
inhibitor prescription in the wash-out period, or both the risk and
reference periods, did not contribute to the analysis.
Hospitalizations included emergency department visits and
hospital admissions for bradycardia, and were identified using the
International Classification of Diseases and Related Health
Problems Tenth Revision (ICD-10) [29] code for bradycardia
(R001). All hospital visits associated with a diagnosis of
bradycardia were included in this study because the CIHI
Discharge Abstract Database does not contain direct information
on the primary reason for hospital admission. The date of the
hospitalization served as the index date, and only the first
hospitalization for bradycardia was considered for patients with
multiple such admissions during the study period.
Identification of Control Patients
In keeping with the case-time-control design, we corrected for
temporal changes in cholinesterase inhibitor use by matching each
case with up to three control patients. Control patients did not
experience a hospitalization for bradycardia on or before the index
date, but did receive at least one prescription for a cholinesterase
inhibitor in either of the corresponding risk or reference intervals
preceding the index date (Figure 1).
To minimize differences between case and control patients, we
selected controls matched on age (born within 1 y of case), sex,
and their anticipated risk of bradycardia using a disease risk index,
as done previously [30,31]. The disease risk index was derived by
constructing a multivariable regression model that included
multiple potential predictors of bradycardia or death, including
socioeconomic status, residence in long-term care facility, overall
number of prescription drugs prescribed in the preceding year,
beta-blockers, calcium channel blockers, digoxin, antiarrhythmics,
nitrates, anticoagulants, antiplatelets, diuretics, angiotensin-con-
verting enzyme inhibitors, angiotensin receptor blockers, HMG-
CoA reductase inhibitors, fibric acid derivatives, ezetimibe, oral
hypoglycemic agents, insulin, antipsychotic medications, antide-
pressants, sedative-hypnotics, chemotherapy, corticosteroids, over-
all number physician clinic visits, emergency department visits,
cardiologist visits, internist visits, neurologist visits, geriatrician
visits, psychiatrist visits, coronary artery bypass graft, angiography,
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carotid endarterectomy, peripheral vascular disease procedures,
dialysis, echocardiography, electrocardiography, holter monitor,
nuclear medicine stress test, carotid doppler ultrasonography,
charlson comorbidity index score, renal dysfunction, liver
dysfunction, heart failure, diabetes, cancer, cerebrovascular
disease (strokes, transient ischemic attacks), cardiac dysrhythmias,
myocardial infarction, angina and coronary artery disease,
peripheral vascular disease, major infections (respiratory, urogen-
ital, abdominal, gastrointestinal, skin, soft tissue), and alcoholism
(Text S1). These potential confounders were consequently
summarized into a single disease risk index that predicted the
probability of hospital admission for bradycardia [30,32]. We
selected up to three controls with the disease risk scores (within 0.2
standard deviation) closest to the given case.
Statistical Analysis
We derived the case-time-control odds ratio [OR] by dividing
the crossover OR among the cases (i.e., the case-crossover group)
by the crossover OR among the controls (i.e., the control-crossover
group), thereby producing a case-control OR adjusted for time-
trend (Figure 1). Crossover ORs were derived from the ratio of
discordant pairs, i.e., the number of individuals exposed
exclusively during the risk interval as compared to exclusively
during the reference interval [27]. By assuming conditional
independence of exposure within each 1:3 matched set, a
conditional logistic regression model, adjusting for the length of
stay in hospital in the year preceding study entry as an additional
measure of comorbidity, was fitted to estimate the overall OR and
95% confidence intervals (CIs) [27].
We hypothesized that individuals with pre-existing cardiovas-
cular disease and individuals co-using negative chronotropic
agents might be at particularly high risk for bradycardia. To
examine these risk groups, we performed a stratified analysis in
those with a history of cardiovascular disease (defined as previous
myocardial infarction, congestive heart failure, angina, or
arrhythmias), and those coprescribed negative chronotropic
medications such as beta-adrenergic antagonists, digoxin, or the
nondihydropyridine calcium channel antagonists verapamil and
diltiazem.
Drug interactions with cholinesterase inhibitors can occur via
the cytochrome P450 enzyme 2D6. However, given the relatively
few P450 2D6 inhibitors, we felt it was more relevant to focus on
the pharmacodynamic interaction between cholinesterase inhibi-
tors and negative chronotropic agents.
Figure 1. Case-time-control design.
doi:10.1371/journal.pmed.1000157.g001
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analysis in which proton pump inhibitors served as the exposure of
interest rather than cholinesterase inhibitors. All analyses used a
two-sided type I error rate of 0.05 and were performed using SAS
version 9.1 (SAS Institute).
Results
Between January 1, 2003 and March 31, 2008, we identified
27,333 hospitalizations for bradycardia among Ontario residents
67 y and older. Of these, 10,323 were excluded because they were
hospitalized in the year prior to the index date, and 15,805 were
excluded because they had not used cholinesterase inhibitors in the
9 mo prior to index date (Figure 2). Among the remaining
patients, we further excluded 191 individuals exposed to
cholinesterase inhibitors during the wash-out interval, and patients
who had a pacemaker or could not be matched to at least one
control (n#5), leaving 1,009 eligible cases. Among these cases, 848
(84%) received a cholinesterase inhibitor in both the risk and
reference periods, leaving 161 cases to inform our matched pairs
analysis of individuals who had received a cholinesterase inhibitor
in either the risk or reference period, but not both. Of these cases,
148 (92%) were fully matched to three controls and 157 (98%)
were matched to at least two controls. We identified 466 matched
controls from 42,833 potential controls.
The characteristics of cases and controls were highly similar
(Table 1). The mean age of patients was 83 y (standard deviation
5.4 y) and 320 (51%) were female. A higher proportion of controls
were in long-term care facilities, although the overall proportion
remained low in both groups. Donepezil was the most frequently
prescribed cholinesterase inhibitor in these patients accounting for
117 of the 161 (73%) cases and 292 of the 466 (63%) controls.
Seventeen patients (11%) received a pacemaker during their
hospitalization, and six (4%) individuals died prior to discharge
from hospital.
In the primary analysis, recent initiation of cholinesterase
inhibitors was significantly associated with hospitalization for
bradycardia (adjusted OR 2.13, 95% CI 1.29–3.51, p=0.003;
Table 2). Among cases and controls with previously diagnosed
cardiac disease, the association between recent use of cholinesterase
inhibitors and bradycardia was similar (adjusted OR 2.25, 95% CI
1.18–4.28, p=0.014). The association persisted among the cases
and controls receiving negative chronotropic medications (adjusted
OR 2.34; 95% CI 1.16–4.71, p=0.017). As expected, we found no
association between recent initiation of proton pump inhibitors and
bradycardia (adjusted OR 1.13, 95% CI 0.93–1.37, p=0.228).
Figure 2. Flow diagram of case selection.
doi:10.1371/journal.pmed.1000157.g002
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Because bradycardia is a relatively common occurrence in older
patients, we hypothesized that the potential contribution of
cholinesterase inhibitors to the development of bradycardia might
not be recognized, and that therapy might be continued following
discharge. After excluding individuals who received pacemakers
during their hospital stay, 138 cases survived to discharge. Of these
cases, subsequent prescription records indicated that cholinester-
ase inhibitors were restarted in 78 individuals (57%) within 100 d
of hospital discharge. A post hoc examination of the 3-mo period
following resumption of therapy in those 78 individuals showed
that three (3.8%) individuals were readmitted to hospital or visited
the emergency department with a diagnosis of bradycardia.
Discussion
Using the health care records of more than 1.4 million Ontario
residents aged 67 y and older, we found that treatment with
cholinesterase inhibitors was associated with a doubling in the risk
of hospitalization for bradycardia. Importantly, although cholin-
esterase inhibitors are reversible precipitants of bradycardia, the
drugs were resumed following discharge in greater than half the
cases, presumably because the potential causative role of these
Table 1. Characteristics of cases and controls.
Characteristic
Cases
(n=161)
Controls
(n=466)
Age, mean (SD), y 82.8165.41 82.7165.37
Female 82 (50.9%) 238 (51.1%)
Low income 42 (26.1%) 124 (26.6%)
Charlson Index, mean score (SD) 0.7661.27 0.6761.19
Long-term care, preceding year 8 (5.0%) 46 (9.9%)
Drug therapy, preceding year
ACE inhibitor 58 (36.0%) 176 (37.8%)
Angiotensin receptor antagonist 18 (11.2%) 61 (13.1%)
Antiarrhythmic #5 18 (3.9%)
Anticoagulant 27 (16.8%) 70 (15.0%)
Antidepressant 33 (20.5%) 93 (20.0%)
Antiplatelet 28 (17.4%) 92 (19.7%)
Antipsychotic 9 (5.6%) 21 (4.5%)
Beta-adrenergic antagonist 53 (32.9%) 149 (32.0%)
Calcium channel antagonist 47 (29.2%) 145 (31.1%)
Corticosteroid #5 #5
Digoxin 25 (15.5%) 63 (13.5%)
Diuretic 57 (35.4%) 156 (33.5%)
Fibric acid derivative #5 8 (1.7%)
Oral glucose lowering drug 21 (13.0%) 52 (11.2%)
Insulin #5 12 (2.6%)
Nitrate 18 (11.2%) 55 (11.8%)
Sedative hypnotic 22 (13.7%) 72 (15.5%)
Statin 41 (25.5%) 123 (26.4%)
Total n drugs prescribed in
preceding year, median (IQR)
8 (5–12) 8 (5–12)
Total n physician visits in preceding year
Cardiologist
Mean6SD 0.5261.06 0.4461.51
Median (IQR) 0 (0–1) 0 (0–0)
Family physician
Mean6SD 13.88613.88 13.75612.07
Median (IQR) 10 (5–18) 11 (6–18)
Geriatrician
Mean6SD 0.1760.84 0.1760.68
Median (IQR) 0 (0–0) 0 (0–0)
Internist
Mean6SD 2.2064.71 1.9664.90
Median (IQR) 1 (0–2) 1 (0–2)
Neurologist
Mean6SD 0.0860.33 0.0860.36
Median (IQR) 0 (0–0) 0 (0–0)
Psychiatrist
Mean6SD 0.3663.19 0.4562.90
Median (IQR) 0 (0–0) 0 (0–0)
Total n emergency department
visits, preceding year
0.7361.65 0.7761.71
Total n medical visits, preceding year 22.81619.62 22.19617.81
Total n days stayed in hospital,
preceding year
2.0266.27 1.9567.29
Characteristic
Cases
(n=161)
Controls
(n=466)
Medical conditions, preceding 5 y
Heart failure 28 (17.4%) 90 (19.3%)
Myocardial infarction 74 (46.0%) 230 (49.4%)
Peripheral vascular disease #5 #5
Alcoholism #5 19 (4.1%)
Angina 49 (30.4%) 160 (34.3%)
Arrhythmia 15 (9.3%) 31 (6.7%)
Diabetes 42 (26.1%) 109 (23.4%)
Liver disease #5 11 (2.4%)
Renal dysfunction 57 (35.4%) 146 (31.3%)
Stroke 41 (25.5%) 112 (24.0%)
Medical procedures, preceding 5 y
Coronary artery bypass graft #5 7 (1.5%)
Percutaneous transluminal coronary
angioplasty
7 (4.3%) 19 (4.1%)
Peripheral vascular disease 0 (0.0%) #5
Angiography/cardiac catheterization 9 (5.6%) 23 (4.9%)
Carotid doppler ultrasound 35 (21.7%) 107 (23.0%)
Carotid endarterectomy #5 #5
Dialysis 0 (0.0%) 0 (0.0%)
Echocardiogram 70 (43.5%) 212 (45.5%)
Electrocardiography 144 (89.4%) 418 (89.7%)
Holter monitoring 52 (32.3%) 141 (30.3%)
Stress and nuclear tests 50 (31.1%) 147 (31.5%)
Valve surgery 0 (0.0%) 0 (0.0%)
All data presented as number (percentages) except where indicated. Cells #5
are suppressed.
ACE, angiotensin-converting enzyme; IQR, interquartile range; SD, standard
deviation.
doi:10.1371/journal.pmed.1000157.t001
Table 1. Cont.
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cholinesterase inhibitors are associated with marginal improve-
ment in cognition and global functioning [1,33]. Consequently,
recent guidelines suggest that cholinesterase inhibitors should not
be standard of care for patients with dementia, but instead urge
physicians to weigh each individual’s expected risks and benefits
before initiating therapy. Our large-scale population-based
assessment of the risk of bradycardia with cholinesterase inhibitors
in clinical practice should help inform the risk-benefit assessment
for clinicians and patients. A recent study used an alternate cohort
design to examine a primary outcome of syncope in patients
receiving cholinesterase inhibitors. In a secondary analysis, these
investigators also observed an elevated risk of bradycardia
(adjusted hazard ratio 1.69; 95% CI 1.32–2.15) associated with
cholinesterase inhibitor use, which complements the findings of
our study [34].
The risk of bradycardia observed in our study may cause
clinicians and patients to reconsider therapy with these drugs,
particularly for patients in whom little or no cognitive improve-
ment is observed early in therapy [35,36]. At a minimum, our
findings should alert clinicians to the potential role of cholinester-
ase inhibitors in patients with bradycardia, for whom resumption
of treatment may be inadvisable.
Our study has several limitations that merit emphasis.
Administrative databases contain information on hospitalizations,
emergency department visits, diagnoses, procedures, physicians’
claims, outpatient clinic visits, and drug dispensing data. However,
they lack the clinical richness of a medical chart. Accordingly, we
were not able to capture the severity of dementia, lifestyle habits
such as smoking, diet, alcohol use, exercise, over-the-counter drug
use, in-hospital drug use, laboratory values, and the results of
diagnostic testing.
However, we relied on the unique crossover design feature that
controls for fixed patient characteristics by allowing each patient to
serve as his or her own control. Consequently, concerns regarding
potential confounders, including disease severity, were largely
overcome. The crossover design also relies on the temporal
association between an exposure and outcome, and this feature
enabled us to examine whether bradycardia-related hospitalization
was likely secondary to cholinesterase inhibitors as opposed to
underlying comorbidities. More specifically, the crossover design
examines whether an exposure is more likely to occur immediately
preceding an event or during another period when bradycardia
did not occur. If the exposure is not associated with the outcome,
then no temporal association would be expected. The presence of
underlying comorbidities would not be expected to confound the
cholinesterase inhibitor–bradycardia relationship unless the co-
morbidities were associated with both cholinesterase inhibitor use
and bradycardia. To further control for confounding, we corrected
for temporal changes in cholinesterase inhibitor use by matching
each case with up to three control patients on the basis of an
extensive disease risk index score.
We identified episodes of bradycardia resulting in emergency
department visits or hospital admissions, but we were unable to
identify individuals in whom bradycardia did not culminate in
hospital care, including cases in which bradycardia led to death
[37]. Therefore, our analysis likely underestimates the true risk of
cardiovascular harm associated with cholinesterase inhibitors. The
coding for bradycardia has not been validated and it is possible
that some cases of bradycardia were missed if the code for
bradycardia has low sensitivity. However, we expect that the
positive predictive value for the bradycardia code would be
reasonable because the diagnosis for bradycardia is based upon a
fairly straightforward medical assessment. The occurrence of
random miscoding would only have attenuated our estimates and
biased the results towards the null. It is likely that the cases of
bradycardia captured in our study were clinically significant
because they were severe enough to be documented in the
patient’s chart and coded in the CIHI database.
We were unable to assess the absolute risk of bradycardia due to
cholinesterase inhibitor therapy, and we could not be certain that
resumption of cholinesterase inhibitors following hospital dis-
charge truly reflected a lack of appreciation for the potential
negative chronotropic effects of therapy. Since most patients were
taking donepezil, we were not able to contrast risks with individual
cholinesterase inhibitors given the low prevalence of use with the
other agents. Future studies are needed to address the relative
harms of the individual drugs in this class.
Our post hoc examination of the 78 patients who resumed
cholinesterase inhibitor after hospital discharge showed that only
4% were readmitted to hospital or visited the emergency
department with a diagnosis of bradycardia in the 3 mo following
resumption of therapy. It is hard to know how to interpret this post
hoc analysis. We did not evaluate out-of-hospital death, and could
Table 2. Risk of bradycardia-related hospital admissions and recent cholinesterase inhibitor use.
Overall and Subgroup Analyses Exposure in Risk Interval Exposure in Reference Interval Adjusted OR
a (95% CI)
Full population
Overall 2.13 (1.29–3.51)
Cases (n=161) 139 22 p=0.003
Control (n=466) 349 117
I. Subgroup with cardiac comorbidity
Overall 2.25 (1.18–4.28)
Cases (n=97) 84 13 p=0.014
Control (n=274) 202 72
II. Subgroup using negative chronotropes
Overall 2.34 (1.16–4.71)
Cases (n=80) 69 11 p=0.017
Control (n=220) 158 62
aCase-time-control OR adjusted for hospitalization length of stay in the preceding year.
doi:10.1371/journal.pmed.1000157.t002
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with a reduced dose or more gradual dose titration, whether
changes to other medications were made, or whether closer
outpatient follow up for bradycardia was undertaken.
Finally, because we relied on drug dispensing data as a proxy for
drug adherence, there was a potential for exposure misclassification.
While bias and confounding can threaten any observational
study, the likelihood of these was reduced substantially by the
design of our study, in which every case served as his or her own
control, thereby lessening between-patient variability, and by the
use of a disease risk index, an advanced matching technique,
which resulted in considerable similarity between cases and
controls (Table 1) [31,32].
In summary, we found that cholinesterase inhibitors are
associated with a significantly increased risk of hospitalization for
bradycardia among older outpatients, and that the risk is similar in
patients with cardiovascular comorbidity and those receiving
concurrent therapy with negative chronotropic drugs. Our
findings highlight the importance of careful clinical evaluation
prior to initiating cholinesterase inhibitor therapy, and vigilant
monitoring thereafter in order to prevent adverse cardiac events.
Cholinesterase inhibitors should be prescribed judiciously, and
because these drugs carry a risk of serious adverse events, they
should be continued only if the benefits outweigh the risks. Finally,
it is important for clinicians to be aware of the potential negative
chronotropic effects of cholinesterase inhibitors, and reassess the
merits of continued therapy in patients who develop bradycardia
while taking these drugs. The frequent resumption of cholinester-
ase inhibitors following discharge suggests that bradycardia may
not be widely recognized as a potential adverse effect of this class
of medications.
Supporting Information
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Background. Alzheimer disease and other forms of
dementia principally affect people aged over 65. These
conditions result in confusion, long term memory loss,
irritability, and mood swings. As the population of developed
countries ages, the prevalence of dementia is expected to
increase significantly. It is forecast that the proportion of
people with dementia in the US will quadruple by 2045.
A common treatment for Alzheimer disease is a class of drug
called an acetylcholinesterase inhibitor or cholinesterase
inhibitor. These include donepezil (brand name Aricept),
rivastigmine (marketed as Exelon and Exelon Patch), and
galantamine (branded Razadyne).
The benefit of taking cholinesterase inhibitors is generally
small and they cannot reverse the effects of dementia. In
about 50% of patients they delay the worsening of
symptoms for between six months and a year, although a
small number of patients may benefit more. They can have
unpleasant side effects, which may include diarrhoea and
muscle cramps.
Why Was This Study Done? Existing evidence is
inconclusive on whether cholinesterase inhibitors increase
the risk of bradycardia, an abnormally slow resting heart rate
of below 60 beats a minute, which can cause fatigue,
dizziness, fainting, palpitations, shortness of breath, or death.
In this paper, the authors use routinely collected health care
data to investigate whether an older person taking a
cholinesterase inhibitor is at increased risk of bradycardia.
What Did the Researchers Do and Find? They began by
supposing that cholinesterase inhibitors might induce
bradycardia soon after a patient first began to take them.
To investigate this, they obtained health care data on 1.4
million patients aged 67 or over in Ontario, Canada. They
identified 161 patients who had visited a hospital for
bradycardia and who had previously taken a cholinesterase
inhibitor only within specific periods of time. They found that
139 had taken a cholinesterase inhibitor within the previous
three months compared with 22 who had stopped taking it
at least six months before.
They compared these cases with up to three ‘‘control’’
patients who matched each of the initial ‘‘case’’ group of 161
patients by age, sex, and risk of bradycardia on the basis of
their general health. None of the 466 controls had visited a
hospital for bradycardia by the ‘‘index date,’’ that is, the date
of hospitalization of the case patient they matched. The
researchers found 349 of the control patients had begun to
take a cholinesterase inhibitor in the three months prior to
the index date, compared with 117 who had stopped taking
it at least six months before. A statistical analysis of these
data showed that recent initiation of cholinesterase inhibi-
tors was associated with approximately a doubling of the risk
of hospitalization for bradycardia.
The authors repeated their procedure to see whether
another class of drug, proton pump inhibitors, had a similar
effect. As they had expected, it did not. They repeated the
analysis for patients taking into account other drugs that
slow the heart rate and found that their increased risk of
bradycardia when taking a cholinesterase inhibitor persisted.
The increase in risk was also similar in patients with pre-
existing heart problems.
The researchers’ data also showed that, excluding patients
who while in the hospital had a pacemaker fitted to control
their heart rate, over half of the patients released from
hospital started taking a cholinesterase inhibitor again. Of
these, a few returned to hospital with bradycardia within 100
days.
What Do These Findings Mean? Recent guidelines
suggest that doctors should not prescribe cholinesterase
inhibitors for dementia patients as a matter of course, but
weigh the potential risks and benefits. This paper provides
evidence of an additional risk, of which at least some doctors
are unaware. It was not possible to compare risk for different
cholinesterase inhibitors because most patients took
donepezil.
A population-based study like this cannot prove that
cholinesterase inhibitors cause bradycardia. The authors
used routinely collected data and so did not have
information on all relevant risk factors, and thus there
remains a possibility of bias due to unmeasured factors. In
addition the authors had to make assumptions, for instance
that patients took the drugs prescribed for them. They also
considered only diagnoses of bradycardia made by a hospital
doctor and not those made elsewhere, which means the
incidence of bradycardia may have been underestimated. A
strength of the study is the use of a case-time-control design,
which has the advantage of reducing bias due to the
different health conditions and lifestyle of individual
patients, and also bias due to factors changing over time.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000157.
N Wikipedia contains information on Alzheimer disease (note
that Wikipedia is a free online encyclopedia that anyone
can edit; available in several languages)
N Information on bradycardia and its causes can be found in
Wikipedia (note that Wikipedia is a free online encyclope-
dia that anyone can edit; available in several languages)
N The UK’s National Health Service provides information on
dementia, including symptoms, causes, diagnosis, treat-
ment, and prevention
N MedlinePlus provides US-based health information (in
English and Spanish)
N The US National Institute on Aging provides information
on health, relevant to older people, including Alzheimer
Disease and dementia (in English and Spanish)
N The US Alzheimer’s Association contains useful information
on the disease, including on medication
N The Public Health Agency of Canada website provides
information on senior health (in English and French)
N The UK-based Alzheimer’s Society provides advice on
caring for people with dementia
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